Godavari Drugs Ltd (GODAVARI) is currently trading at 120.53 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Godavari Drugs Limited manufactures Active Pharmaceutical Ingredients (API) and drug intermediates with a focus on Sulphamethoxazole (SMX), a commonly used antibiotic with robust export demand. The company has strategically expanded its SMX capacity and integrated backward into producing important drug intermediates, enhancing value addition and operational efficiency. Diversification into Trimethoprim (TMP), which is used with SMX for treating infections, further positions the company to leverage combination therapies. Godavari Drugs applies its chemistry expertise across various stages, from lab research to commercial production, underlining its capability in scaling up from pilot projects to large-scale manufacturing. Continuous product development is evident with the planned increase in capacity for 'Pyrazyamide' and exploration of new products like Cislactum for anti-anginal drugs.

Over the past 52 weeks, Godavari Drugs Ltd has traded between a low of ₹69.70 and a high of ₹135.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Godavari Drugs Ltd has a market capitalization of approximately 118.96. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Godavari Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 118.96 Cr, Godavari Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Godavari Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Godavari Drugs Ltd is 28.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Net profit was Rs 1.29 crore and net sales were Rs 33.16 crore for the quarter ended March 2026.